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Introduction: Chronic headaches are not a rare condition in children and adolescents
with negative effects on their quality of life. Our aims were to investigate the clinical
features of chronic headache and usefulness of the International Classification of
Headache Disorders 3rd edition (ICHD 3) criteria for the diagnosis in a cohort of
pediatric patients.
Methods: We retrospectively reviewed the charts of patients attending the Headache
Center of Bambino Gesù Children and Insubria University Hospital during the 2010–2016
time interval. Statistical analysis was conducted to study possible correlations between:
(a) chronic primary headache (CPH) and demographic data (age and sex), (b) CPH
and headache qualitative features, (c) CPH and risk of medication overuse headache
(MOH), and (d) CPH and response to prophylactic therapies. Moreover, we compared
the diagnosis obtained by ICHD 3 vs. ICHD 2 criteria
Results: We included 377 patients with CPH (66.4% females, 33.6% males, under 18
years of age). CPHwas less frequent under 6 years of age (0.8%; p< 0.05) and there was
no correlation between age/sex and different CPH types. The risk to develop MOH was
higher after 15 years of age (p < 0.05). When we compared the diagnosis obtained by
ICHD 2 and ICHD 3 criteria we found a significant difference for the undefined diagnosis
(2.6% vs. 7.9%; p < 0.05), while the diagnosis of probable chronic migraine was only
possible by using the ICHD2 criteria (11.9% of patients; p < 0.05). The main criterion
which was not satisfied for a definitive diagnosis was the duration of the attacks less
than 2 h (70% of patients younger than 6 years; p < 0.005). Amitriptyline and topiramate
were the most effective drugs (p < 0.05), although no significant difference was found
between them (p > 0.05).
Conclusion: The ICHD 3 criteria show limitations when applied to children under 6 years
of age. The risk of developing MOH increases with age. Although our “real word” study
Papetti et al. Retrospective Analysis of an Italian Cohort
shows that amitriptyline and topiramate are the most effective drugs regardless of the
CPH type, the lack of placebo-controlled data and the limited follow-up results did not
allow us to conclude about the drug efficacy.
Keywords: chronic headache, children, chronic migraine, tension-type headache, medication overuse headache,
prophylactic therapy
INTRODUCTION
Chronic primary headaches (CPH) are a disabling disorder for
children, adolescents, and adults, with a reported prevalence of
2% in adults and 0.78% in adolescents, while the prevalence rises
up to 1.75%when including theMOH (1). Nearly 69% of children
and adolescents who present to headache specialty clinics have
chronic migraine (1). In adolescents and children suffering from
this condition, attacks may interfere with the predictability of
normal life activities and affect the ability to work, perform
routine course and school activities, and maintain functional
social relations. CPH determines a huge decrease of the quality
of life (1).
Chronic migraine (CM), chronic tension-type headache
(CTTH) and new daily persistent headache (NDPH) are classified
as CPH in the International Classification of Headache Disorders
3rd edition (ICHD 3). Medication-overuse headache (MOH) is
classified among secondary headaches, but it generally affects
patients with a pre-existing primary headache. The least common
denominator of all these forms of CPH is the persistence of the
symptoms for at least 3 months, while the clinical features can
vary (2).
CPH may be improved by non-pharmacological treatment,
such as lifestyle modifications and complementary therapies
(i.e., cognitive behavioral therapy), and/or pharmacological
prophylaxis (3).
There are few data concerning the characterization of CPH in
the pediatric population, so that most our knowledge emerges
from the experience in adulthood. The latest version of the
International Classification (ICHD 3) does not include notes for
the diagnosis of CPH in pediatric age, although CPH is reported
as an increasing condition in children and adolescents with
distinct clinical features compared to the adult population (4).
The aims of our “real word” study were: (1) to describe
the features of chronic headache in children, and (2) to
compare the diagnostic usefulness of ICHD 2 (5) and
ICHD 3 criteria. As a secondary aim, we will describe
retrospective data of efficacy of the commonly used prophylactic
pharmacological therapies.
METHODS
We retrospectively reviewed the charts of patients attending
to the tertiary, university-affiliated, pediatric medical Headache
Centers of Bambino Gesù Children and Insubria University
Hospital. The design of the study is resumed in Figure 1. The
electronic database of the headache clinics was searched for
all children and adolescents up to 18 years of age, diagnosed
with CPH during the 2010–2016 time interval. Moreover, in
CPH population a history of drug overuse supporting the
diagnosis of MOH was looked for. The diagnosis was re-
evaluated in all cases by using the ICHD-III criteria (2). The
main inclusion criteria was history of headache occurring on
15 or more days/month for more than 3 months. Exclusion
criteria were headache types other than CPH and the presence
of other internist and/or neurological illness. We considered
the following CPH types: CM, CCTH, and NDPH. Data on
demographics, headache symptoms, and other clinical headache-
related parameters were collected from the medical files of the
patients who were found eligible to be included in the study.
Electronic medical records included the following information:
demographic data (age, sex), familiar medical history including
headaches, pregnancy and birth history, past medical history,
anthropometrical data (weight and height), general physical
exam and neurological exam including fundus oculi. Medical
charts included also results of possible neuroimaging exams
and the data from headache diary. Headache diary reports the
number of the attacks for months, duration of the attacks,
qualitative features of pain, presence of associated symptoms
(nausea, vomiting, phonophobia, and photophobia), intensity of
pain, name of drug for the attack and response to therapy for
the attack.
Patients were divided into four age groups: 0–6, 7–10, 11–15,
and 15–18 years.
Clinical data, concerning duration, qualitative features of
the headache attacks, related symptoms and prophylactic
pharmacologic therapies were issued from the first and follow
up visits. These data were collected from interviews to
children and/or their parents. For very young children headache
frequency and symptoms were determined by the child’s
complaints and the parents’ impression from the child’s behavior
(according to the ICHD-III criteria) (2). In addition, parents were
questioned about possible medication overuse of their child. The
medical interview was always followed by a complete full physical
and neurological examination of the patient.
Statistical analysis was conducted by SPPS version 22.0
and χ2 test was used to verify possible correlations between:
(a) CPH subtypes and population features (age and sex), (b)
CPH subtypes and headache qualitative features (nausea,
vomiting, phonophobia, and photophobia), (c) predictors of
development MOH, and (d) CPH and response to prophylactic
therapies (amitriptyline, topiramate, flunarizine, and L-5
hydroxytryptophan). In addition, we performed a comparison
between ICHD 2 and ICHD 3 criteria for the diagnosis. A p-value
of ≤0.05 was considered significant.
Written informed consent was obtained from the parents of
the participants in this study. The study was approved by the
Ethical Committee of Bambino Gesù Children Hospital.
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FIGURE 1 | Study methods design.
RESULTS
Descriptive Analysis of Chronic Headache
Characteristics and Clinical Correlations
We included 377 patients who experienced chronic headache
(66.4% females, 33.6% males; p > 0.05). Mean age of selected
patients was 10.8 years ± 2.5 standard deviation (SD) (range
3.20–18 years). Pain quality, intensity and frequency of the
attacks, and associated symptoms are shown in Table 1.
CPH was less frequent under 6 years of age (0.8%; p <
0.05), while a significant higher prevalence of CPH was found
in females than in males in the age group between 0 and
6 years (23/31 females, 8/31 males) and between 15 and 18
years (41/51 females, 10/51 males) (p < 0.05). No significant
statistical correlation between age/sex and different CPH types
was found. Nausea and vomiting were the two most frequent
vegetative symptoms under 10 years of age (p < 0.05) while
photo/phonophobia were more frequent in patients older than
15 years (p < 0.05).
As for attack duration, three groups of patients were identified:
(1) attack duration was shorter than 1 h in 122 patients (32.3%),
(2) it ranged between 1 and 2 h in 150 patients (39.7%), and
(3) it was longer than 2 h in 105 patients (27.8%). When
the different age-based groups of patients were considered, a
significant different distribution of the attack duration was found.
In particular, we found that an attack duration shorter than 2 h
was more frequent in the patients between 0 and 6 year (70%) as
compared to other groups (39.5% in patients between 7 and 10
years, 24.5% in patients between 11 and 14 years and 13.7% in
patients older than 14 years) (p < 0.05). As consequence of this
phenomenon we detected that the distribution of CH subtypes
tends to overlap in the age groups between 7 and 10 years, 11–
14 years and above 15 years while in patients younger than 6
years, we have a significant increase in the frequency of probable
or undefined diagnoses (p < 0.05) (Figure 2). The most frequent
parameter that did not fill the criteria for a definitive diagnosis in
patients under 6 age, was the duration of the attack less than 2 h.
MOH was found in 10.8% of patients and interested only
patients with CM and CTTH (Figure 3). Ibuprofen was the most
frequently overused drug. Excluding the overuse of drugs for
the attack, we found that the only clinical factor associated with
higher risk to develop MOH was the increasing age (OR 2.2; CI
1.2–4.21; p < 0.05) (Figure 4).
Comparison Between ICHD 3 and ICHD 2
Criteria
According the last version of ICHD, the most frequent
diagnosis was CM (67.1%), followed by CTTH (12.2%), NDPH
(12.2%), undefined (7.9%), and probable CCTH (pCCTH, 0.5%).
Concomitant history of MOH was detected in 41/337 patients
(10.8%), among whom 31 suffered from CM and 10 from CTTH.
When we used the ICHD 2, CM was diagnosed in 60.4% of
patients, probable CM (pCM) in 11.9%, CCTH in 9.5%, pCCTH
in 3.1%, NDPH in 12.2%, and undefined in 2.6%.
When the diagnoses obtained by ICHD 2 and ICHD 3 were
compared, significant differences of frequencies were found for
pCM (11.9 vs. 0%; p < 0.05) and undefined diagnosis (2.6 vs.
7.9%; p < 0.05) (Figure 5). When we considered the total of
patients who did not receive a conclusive diagnosis (probable and
undefined) we found that for ICHD 2 was 17.6% and ICHD 3 was
8.4% (p > 0.05).
CPH Subtype Predictors
As we have done in the past for episodic primary headache
(6), we used a multivariate logistic regression analysis to
identify headache features and associated symptoms correlated
with a correct diagnosis. We found that the presence
of photophobia/phonophobia and nausea/vomiting were
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TABLE 1 | Headache characteristics in our sample.
AGE OF PATIENTS
0–6 years 31/377 (8.2%)
7–10 years 144/377 (38.2%)
11–14 years 151/377 (40.1%)
15–18 years 51/377 (13.5%)
HEADACHE TYPES (ICHD 3)
Chronic Migraine (CM) 253/377 (67.1%)
Chronic Tensive Type Headache (CTTH) 46/377 (12.2%)
Probable CTTH 2/377 (0.5%)
New Daily Persistent Headache (NDPH) 46/377 (12.2%)
Medication Overuse Headache (MOH) 41/377 (10.8%)
Undefined 30/377 (7.9%)
PAIN QUALITY
Throbbing 94/377 (24.9%)
Gravative 113/377 (29.9%)
Pressing 61/377 (16.1%)
Other qualities 109/377(28.9%)
PAIN INTENSITY
Mild 75/377 (19.8%)
Moderate 132/377 (35%)
Severe 170/377 (45%)
ATTACK DURATION
Less than 1 h 122/377 (32.3%)
Between 1 and 2 h 150/377 (39.7%)
More than 2 h 105/377 (27.8%)
ASSOCIATED SYMPTOMS
Photophobia 225/377 (59.6%)
Phonophobia 258/377 (68.4%)
Nausea and/or vomiting 172/377 (45.6%)
significantly associated with the diagnosis of both CM [Odd
Ratio (OR) 2.8; confidence interval (CI) 1.76–4.6; positive
predictive value (PPV) 81%; p < 0.05] and pCM (OR 2.5; CI
1.5–4.1; PPV 78%; p < 0.05), whereas it was not associated with
the diagnosis of both CCTH (OR 0.17; CI 0.1–0.3; VPP 5%; p <
0.05) and pCCTH (OR 0.2; CI 0.1–0.5; VPP 5%; p < 0.05).
Prophylactic Therapy
Data concerning the use of prophylactic therapy were issued
from 272 patients (72.1%). The drugs used for prophylaxis
included 5-hydroxytryptophan, flunarizine, amitriptyline and
topiramate. The most frequently used drug was amitriptyline
(81.6%), followed by topiramate (21.7%), flunarizine (12%), and
5-hydroxytryptophan (6.9%), while 13.9% of patients needed
more than one drug (Figure 6). Around half of patients (54%)
had a beneficial response (reduction in the frequency of attacks
by at least 50%), while 16.5% of patients showed no improvement.
However, we could not have follow-up data for 29.5% of patients.
Amitriptyline and topiramate were the drugs with higher
percentage of efficacy (p < 0.05) and no significant difference in
efficacy was found between them (p > 0.05) (Figure 7).
DISCUSSION
CPH represents a growing problem in the pediatric and
adolescent age. Our study aimed to fill a lack in the literature
regarding CPH description in pediatric age and to verify if
the changes made in the third version of ICHD could bring
advantages for the diagnosis of CPH in this age group.
The most relevant results of our study were the following:
- ICHD 3 criteria keep presenting limits when applied in
pediatric age, especially in children under 6 years of age. The
main limit concerns the criterion of the duration of the attack.
- We reported the main correlations between CPH
and demographic data and described also the most
frequent phenotypes.
- The MOH prevalence in our population was 10.8%, much
lower than the in adult patients.
- Amitriptyline and topiramate were the most effective drugs in
our CPH patients.
Has ICHD 3 Given an Advantage?
In our CPH population, female sex was prevalent in the age group
between 0 and 6 years and between 15 and 18 years (75% female
vs. 24% male in 0–6 years; 81 vs. 19% above 15 years;). Our
data confirm the findings of studies on both adult and adolescent
chronic headaches which showed an higher frequency in females
than males (7–11).
Though largely overlapping, ICHD 2 and ICHD 3 show some
differences, especially for the non-conclusive diagnoses. These
include the so-called “probable diagnoses” (when one of the
criteria is not met) and “undefined diagnoses” (when more than
one criterion is not met). While the diagnosis of pCM was
possible in the ICHD 2, it was abolished in ICHD 3. Patients
defined as pCM with the ICHD 2 belong to two categories: those
with simultaneous story ofMOH and those who did notmeet one
of the criteria for diagnosis in particular the duration criterion.
According to the ICHD 3, the first ones are re-classified as CM,
while the second ones as undefined (2, 5).
According to ICHD 2, in patients overusing medications
the diagnosis of MOH can be definitely done only if headache
improves after overused medication withdrawal. Before being
diagnosed definitely, patients with medication overuse were
temporarily given a diagnosis of pCM or pCTTH with probable
MOH (5). According to ICHD 3, patients meeting the criteria
for CM/CTTH and MOH should be coded for both. After
drug withdrawal, headache can either revert to an episodic
type or remain chronic, and the patient should be re-diagnosed
accordingly (2). In our patients, the modification in MOH
diagnosis led to a slight increase of CM prevalence from 60.4%
(ICHD 2) to 67.1% (ICHD 3).
While CM can be diagnosed with the ICHD 2 whether the
patient refers at least 15 days a month of headache with the
clinical characteristics of migraine, the ICHD 3 requires that only
eight out of 15 episodes must meet the criteria for migraine.
Therefore, we should expect an increase in the CM frequency.
However, in our patients the CM prevalence did not largely
change passing from the second to the third version of the ICHD.
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FIGURE 2 | Distributions of headache subtypes (ICHD 3) in relation with age.
FIGURE 3 | Number of patients with MOH according to headache subtypes.
This is probably due to the fact that most our chronic patients
with undefined diagnosis did not receive such a diagnosis for the
qualitative characteristics of their headache, but for the duration
of their attacks. Indeed, we found that most children under 6
years of age (70%) could not satisfy the criterion of the attack
duration, often suffering from episodes shorter than 2 h. While
the most frequent phenotype in patients over 6 years of age
was CM, younger patients showed a significant increase in the
prevalence of probable or undefined diagnoses. The associated
symptoms were useful for a diagnosis of primary headache (6).
In particular, the presence of photophobia and phonophobia was
associated with diagnosis of migraine, while the absence of these
symptoms was a predictor of CTTH. The problem of the duration
of the headache attack confirms our previous data showing that
very young children can rarely satisfy the ICHD 3 criteria for the
diagnosis of episodic migraine and TTH (6, 12).
FIGURE 4 | Number of patients with MOH according to patient’s age.
Taking into account the whole amount of our patients who
cannot receive a conclusive diagnosis (probable and undefined),
this percentage dropped from 17.5% with the ICHD 2 criteria to
8.5% with the ICHD 3 criteria. This means that, compared to
the ICHD 2, the latest ICHD version shows a higher diagnostic
power, even if the criteria for children under 6 years of age need
a further improvement.
Medication Overuse Headache in Pediatric
Age
MOH affects 1–2% of the adult general population and 25–50%
of the chronic headache population.
This frequency increased to 30–50% if we consider the
cephalalgic patients followed in specialized headache centers
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FIGURE 5 | Diagnoses obtained by ICHD 2 (black) and ICHD3 (gray) criteria.
FIGURE 6 | Frequencies of patients that received each drug.
FIGURE 7 | Response to therapy (percentages of patients).
(13). As for pediatric age, population surveys conducted in
Taiwan (14) and Norway (15) found that 0.3 and 0.5% of
adolescents respectively could receive a diagnosis of MOH.
Considering the population of children and adolescents suffering
from headache, there are values of MOH prevalence ranging
from 2 to 82.5% (16–20). In our sample, the prevalence of MOH,
diagnosed according to the ICHD 3 criteria, was 10.8%. The
large variability in MOH can be due to several factors, including
differences in genetic background, parenting style, and/or a
pediatricians “approach to headache treatment (17).
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While in adults MOH is more frequent in CM than in
CTTH patients (21), in our young patients there was no
significant difference. The main risk factor associated with the
development of MOH was the age (OR 2.2; CI 1.2–4.21; p
< 0.05). Indeed, the proportion of patients with MOH was
significantly higher in patients over 15 years than in the other
age groups (p < 0.05). This finding is conceivable, since
adolescents can manage the symptomatic drugs by their own
while in younger children the drugs are administered under
parental control.
Pharmacological Treatment of CPH
There are few trials regarding the efficacy of the pharmacological
prophylaxis in young headache patients. Evidence of efficacy
for prophylactic treatment of episodic migraine in children
and adolescents are available for flunarizine, topiramate, and
trazodone (unavailable in the USA), topiramate and trazodone
(22). The use of amitriptyline, combined with psychological
treatment, in patients with CM is supported by one randomized
controlled trial (22, 23). However, clear recommendations
for the prophylactic treatment of CPH pediatric patients are
currently unavailable.
In our population, the most effective drugs were amitriptyline
and topiramate without significant differences between them.
Mack et al., (24) investigated the efficacy of amitriptyline in
patients with high-frequency headache and found that both
headache frequency and intensity significantly improved during
treatment. They underlined that also chronic daily headaches
or continuous headaches appeared to respond to amitriptyline
(24). As for topiramate, its efficacy in the prophylaxis of episodic
migraine at high frequency has been reported (22, 23), while
there are no recommendations for high frequency TTH or
chronic headaches. The good efficacy of topiramate in our
population suggests that this drug should be considered also for
the CPH treatment.
Unfortunately, since follow-up data were missed for a large
proportion of our patients, any consistent conclusion about drug
effectiveness cannot be drawn. Drop-out patients are mainly
those who did not present to the subsequent control visits. There
are 3 main possible reasons for drop-outs: (1) some patients,
who had improved, did not return to the control visit, (2)
other patients, in whom the treatment had not worked, referred
to other centers, and (3) adverse events related to drugs. An
emerging literature demonstrates that patients with migraine and
other headaches hesitate to adhere to pharmacological regimens
(25, 26). The lack of adherence to preventive therapies has
significant consequences on disease severity, frequency of the
attacks and social economics costs. In children and adolescents,
the limit of adherence can be improved not only through an
accurate education of the patient and his/her parents, but also
increasing the evidence about the diagnosis, management and
available therapies.
Limitations of the Study
Our study has some limitations. First, retrospective design of
the study can reduce its reliability in the description of the
clinical CPH features. However, here we present a picture of
pediatric CPH patients referring to third level centers and believe
that our data, including those concerning treatment, can be
representative also of other similar settings. Second, the findings
about the prophylactic treatment are largely affected by the drop-
outs and are not placebo controlled. This last point is particularly
important, considering the open debate about the efficacy of
placebo in children (27–30).
CONCLUSIONS
Literature shows that CPH is a growing phenomenon in the
pediatric population. To date, our study includes the most
extensive Italian CPH children cohort. We showed that the
ICHD3 criteria, though not allowing us to reach a conclusive
diagnosis in 8.5% of cases, represented an improvement
compared to the ICHD 2 criteria, according to which 17.5% of
our patients did not have a definitive diagnosis. The uncertain
diagnoses involved 70% of patients under 6 years, being the attack
duration, shorter than 2 h, the first cause of uncertainty. MOH
prevalence was 10.8% and it was particularly high in patients
older than 15 years. Amitriptyline and topiramate proved the
most effective drugs, regardless of the headache type.
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